Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis

Journal of Bone and Mineral Research

Volumn 25, Issue 9, 2010, Pages 1907-1921

  Aoki, Shigeki ^a   Honma, Masashi ^a   Kariya, Yoshiaki ^a   Nakamichi, Yuko ^b   Ninomiya, Tadashi ^b   Takahashi, Naoyuki ^b   Udagawa, Nobuyuki ^b   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b MATSUMOTO DENTAL UNIVERSITY   (Japan)

Author keywords

Golgi apparatus; OPG; Osteoclastogenesis; Protein sorting; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL MIGRATION; ENZYME LOCALIZATION; GOLGI COMPLEX; HELA CELL; LYSOSOME; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; COCULTURE TECHNIQUES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HELA CELLS; HUMANS; IMMUNOPRECIPITATION; MALE; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OSTEOPROTEGERIN; PROTEIN TRANSPORT; RANK LIGAND;

EID: 77956839811     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.89     Document Type: Article

References (46)

1. Heymann D, Rousselle AV. gp130 Cytokine family and bone cells. Cytokine. 2000;12:1455-1468.
2. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001;276:20659-20672.
3. Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis. 2002;8:147-159. (Pubitemid 34535063)
4. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43:259-269.
5. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science. 2000;289:1508-1514.
6. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412-2424.
7. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem. 2002;277:44347-44356.
8. Naito A, Azuma S, Tanaka S, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 1999;4:353-362.
9. Epker BN, Frost HM. Correlation of Bone Resorption and Formation with the Physical Behavior of Loaded Bone. J Dent Res. 1965;44:33-41.
10. Jimi E, Nakamura I, Amano H, et al. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology. 1996;137:2187-2190. (Pubitemid 26133995)
11. Kariya Y, Honma M, Aoki S, Chiba A, Suzuki H. Vps33a Mediates RANKL Storage in Secretory Lysosomes in Osteoblastic Cells. J Bone Miner Res. 2009;24:1741-1752.
12. Pevsner J, Hsu SC, Hyde PS, Scheller RH. Mammalian homologues of yeast vacuolar protein sorting (vps) genes implicated in Golgi-to-lysosome trafficking. Gene. 1996;183:7-14.
13. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139:1329-1337.
14. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95; 3597-3602.
15. Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem. 1998;273:5117-5123. (Pubitemid 28108672)
16. Shin J, Kim YM, Li SZ, Lim SK, Lee W. Structure-function of the TNF receptor-like cysteine-rich domain of osteoprotegerin. Mol Cells. 2008;25:352-357.
17. Sheikh MS, Fornace AJ, Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia. 2000;14:1509-1513.
18. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
19. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998;247:610-615.
20. Sato N, Takahashi N, Suda K, et al. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. J Exp Med. 2004;200:601-611.
21. Li X, Udagawa N, Takami M, Sato N, Kobayashi Y, Takahashi N. p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages. Endocrinology. 2003;144:4999-5005. (Pubitemid 37378415)
22. Sato M, Nakamichi Y, Nakamura M, et al. New 19-nor-(20S)-1alpha,25- dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro. Bone. 2007;40:293-304.
23. Febbraio M, Silverstein RL. Identification and characterization of LAMP-1 as an activation-dependent platelet surface glycoprotein. J Biol Chem. 1990;265:18531-18537. (Pubitemid 120013745)
24. Tat SK, Padrines M, Theoleyre S, et al. OPG/membranous - RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone. 2006;39:706-715.
25. Theoleyre S, Kwan Tat S, Vusio P, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun. 2006;347:460-467.
26. Williams DB. The Merck Frosst Award Lecture 1994/La conference Merck Frosst 1994. Calnexin: a molecular chaperone with a taste for carbohydrate. Biochem Cell Biol. 1995;73:123-132.
27. Hagiwara H, Tajika Y, Matsuzaki T, Suzuki T, Aoki T, Takata K. Localization of Golgi 58K protein (formiminotransferase cyclodeaminase) to the centrosome. Histochem Cell Biol. 2006;126:251-259.
28. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell. 1987;48:899-907.
29. Schneeweis LA, Willard D, Milla ME. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem. 2005;280:41155-41164. (Pubitemid 41832168)
30. Wahlberg JM, Geffen I, Reymond F, Simmen T, Spiess M. trans-Golgi retention of a plasma membrane protein: mutations in the cytoplasmic domain of the asialoglycoprotein receptor subunit H1 result in trans-Golgi retention. J Cell Biol. 1995;130:285-297.
31. Horowitz MC, Xi Y, Wilson K, Kacena MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev. 2001;12:9-18.
32. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 2001;61:1637-1644.
33. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2000;11:905-913. (Pubitemid 32044070)
34. Nakamura H, Ozawa H. Immunohistochemical localization of heparan sulfate proteoglycan in rat tibiae. J Bone Miner Res. 1994;9:1289-1299.
35. Nakamura H, Hirata A, Tsuji T, Yamamoto T. Immunolocalization of keratan sulfate proteoglycan in rat calvaria. Arch Histol Cytol. 2001;64:109-118.
36. Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone. 2007;41:165-174. (Pubitemid 47001824)
37. Theoleyre S, Wittrant Y, Couillaud S, et al. Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. Biochim Biophys Acta. 2004;1644:1-7. (Pubitemid 38117036)
38. Lazzarino DA, Gabel CA. Mannose processing is an important determinant in the assembly of phosphorylated high mannose-type oligosaccharides. J Biol Chem. 1989;264:5015-5023.
39. Baranski TJ, Faust PL, Kornfeld S. Generation of a lysosomal enzyme targeting signal in the secretory protein pepsinogen. Cell. 1990;63: 281-291. (Pubitemid 20355449)
40. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol. 2003;4:202-212. (Pubitemid 36288042)
41. Doray B, Ghosh P, Griffith J, Geuze HJ, Kornfeld S. Cooperation of GGAs and AP-1 in packaging MPRs at the trans-Golgi network. Science. 2002;297:1700-1703.
42. Ponnambalam S, Baldwin SA. Constitutive protein secretion from the trans-Golgi network to the plasma membrane. Mol Membr Biol. 2003;20:129-139. (Pubitemid 36841703)
43. Golob DS, McAlister WH, Mills BG, et al. Juvenile Paget disease: life-long features of a mildly affected young woman. J Bone Miner Res. 1996;11:132-142.
44. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347:175-184.
45. Chong B, Hegde M, Fawkner M, et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res. 2003;18:2095-2104.
46. Whyte MP, Singhellakis PN, Petersen MB, Davies M, Totty WG, Mumm S. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966-969delT-GACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J Bone Miner Res. 2007;22:938-946.